Evaluation of immunotherapy using dendritic cells and tumor antigen peptide against patients with malignant gliomas

树突状细胞和肿瘤抗原肽对恶性胶质瘤患者免疫治疗的评价

• 批准号: 13671428
• 负责人: NAGANUMA Hirofumi
• 金额: $ 1.98万
• 依托单位: University of Yamanashi Faculty of Medicine
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671428/
• 关键词: glioma; immunotherapy; dendritic cell; tumor-associated antigen; glioma

Recently SART-3 has been shown to be an tumor-associated antigen of malignant gliomas. In this study, we evaluated whether immunological responses are elicited or not after immunization of the patients with gliomas using dendritic cells (DC) pulsed with SART-3 antigen peptide.Eight glioma patients whose HLA types were HLA-A201 and -A24 were selected as candidates for immunotherapy. Peripheral blood lymphocytes (PBL) were separated, DC were induced using several cytokines, DC were pulsed with SART-3 antigen peptide, and then the DC were injected subcutaneously at the neck. The patients received 4 cycles of DC therapy. Before and after the DC Injection, PBL were separated and kept in frozen. Presence of the lymphocytes that are able to recognize the SART-3 antigen peptide was evaluated by enzyme-linked immunospot (ELISPOT) assay. One patient showed some response after the fourth DC immunization, however, 6 patients did not. One patient is waiting for the evaluation.These results indicate that the immunotherapy using DC cells pulsed with SART-3 antigen peptide can induce the lymphocytes which recognize the SART-3 antigen in some glioma patients.

最近，SART-3已被证明是恶性胶质瘤的肿瘤相关抗原。在这项研究中，我们评估了使用SART-3抗原肽脉冲树突状细胞（DC）免疫胶质瘤患者后是否引起免疫反应。选择HLA型分别为HLA- a201和-A24的胶质瘤患者8例作为免疫治疗的候选者。分离外周血淋巴细胞（PBL），用多种细胞因子诱导DC， SART-3抗原肽脉冲DC，颈部皮下注射DC。患者接受4个周期的DC治疗。在DC注射前后，分离PBL并冷冻保存。采用酶联免疫斑点法（ELISPOT）检测能够识别SART-3抗原肽的淋巴细胞的存在。1例患者在第4次DC免疫后出现应答，6例患者无应答。有一个病人在等待评估。这些结果表明，用SART-3抗原肽脉冲DC细胞免疫治疗可诱导部分胶质瘤患者产生识别SART-3抗原的淋巴细胞。